SEC Filing Details

We are a clinical-stage biopharmaceutical company leveraging our proprietary next-generation, non-viral gene engineering technologies to create life-saving cell and gene therapies for patients with high unmet medical need.

SEC Filing Details

Document Details

Form
Filing Date
Dec 28, 2020
Document Date
Dec 16, 2020
Form Description
Initial filing by director officer or owner of more than ten percent.
Filing Group
3,4,5
Company
Poseida Therapeutics, Inc.
Issuer
Poseida Therapeutics, Inc.
Filer
CORNING LUKE